Plamotamab, CAS 2138442-31-4

Product Description: Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742. /[2]Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.

CAS Number: 2138442-31-4

Molecular Weight: N/A

Compound Purity: 99.12

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: CD20;CD3

• Artikelnummer: MEXHY-P99776-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99776-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated